SCHEMBL7143203

SCHEMBL7143203

Clc1ccc(-c2c[nH]c(-c3cnccn3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
PKM P14618 2/20 0.50
NPY5R Q15761 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.40
METAP2 P50579 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP3A4 P08684 1/20 0.38
HSD11B1 P28845 1/20 0.38
KMO O15229 1/20 0.38
PIM1 P11309 1/20 0.37
PIM2 Q9P1W9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29712850 0.85 NPY5R (0.63) NPC1RAB9APKMNPY5RSMN1; SMN2
SCHEMBL28629827 0.85 NPY5R (0.63) NPC1RAB9APKMNPY5RSMN1; SMN2
SCHEMBL29712872 0.85 NPY5R (0.42) NPC1RAB9APKMNPY5RMETAP2
SCHEMBL28641255 0.85 NPY5R (0.42) NPC1RAB9APKMNPY5RMETAP2
SCHEMBL17280232 0.81 GRK6 (0.48) NPY5RMETAP2KMOPIM1PIM2
SCHEMBL28627415 0.80 NPY5R (0.44) NPC1RAB9APKMNPY5RMETAP2
SCHEMBL28632051 0.80 NPC1 (0.43) NPC1RAB9APKMNPY5RSMN1; SMN2
SCHEMBL29712861 0.80 NPC1 (0.43) NPC1RAB9APKMNPY5RSMN1; SMN2
SCHEMBL29712865 0.80 NPY5R (0.44) NPC1RAB9APKMNPY5RMETAP2
SCHEMBL10353034 0.80 RAB9A (0.60) NPC1RAB9APKMNPY5RSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
CN-1265033-A Certain diarylimidaozle derivatives, new class of NPY speific ligands NEUROGEN CORP (US) 2000-08-30 CN disclosed